Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma.

ABSTRACT:

Purpose

Based on improvements of progression-free survival (PFS), new agents for metastatic renal cell carcinoma (mRCC) have been approved. It is assumed that one of the benefits is a delay in health-related quality of life (HRQoL) deterioration as a result of a delay in progression of disease. However, little data are available supporting this relationship. This study aims to provide insight into the most important determinants of HRQoL (including progression of disease) of patients with mRCC.

Methods

A patient registry (PERCEPTION) was created to evaluate treatment of patients with (m)RCC in the Netherlands. HRQoL was measured, using the EORTC QLQ-C30 and EQ-5D-5L, every 3 months in the first year of participation in the study, and every 6 months in the second year. Partic

SUBMITTER: de Groot S 

PROVIDER: S-EPMC5770482 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature